Cytokinetics

Cytokinetics company information, Employees & Contact Information

Explore related pages

Related company profiles:

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, we are developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Proud to be a San Francisco Business Times Best Place to Work in 2021 and 2022, a Great Place to Work-Certified company in 2022 and a part of Fortune's Best Workplaces in the Bay Area in 2022 and Fortune's Best Workplaces in BioPharma in 2022.

Company Details

Employees
634
Founded
-
Address
350 Oyster Point Blvd, South San Francisco,california 94080,united States
Phone
6506243010
Email
me****@****ics.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
South San Francisco, California
Looking for a particular Cytokinetics employee's phone or email?

Cytokinetics Questions

News

Cytokinetics to Announce Third Quarter Results on November 5, 2025 - GlobeNewswire

Cytokinetics to Announce Third Quarter Results on November 5, 2025 GlobeNewswire

Cytokinetics Announces Primary Results from MAPLE-HCM Presented at the European Society of Cardiology Congress 2025 and Published in The New England Journal Of Medicine - Cytokinetics

Cytokinetics Announces Primary Results from MAPLE-HCM Presented at the European Society of Cardiology Congress 2025 and Published in The New England Journal Of Medicine Cytokinetics

Cytokinetics (Nasdaq: CYTK) schedules results for 4:00 PM ET; call at 4:30 PM - Stock Titan

Cytokinetics (Nasdaq: CYTK) schedules results for 4:00 PM ET; call at 4:30 PM Stock Titan

Cytokinetics Announces Call for Proposals for Its Eighth Annual Communications Grant Program - Yahoo Finance

Cytokinetics Announces Call for Proposals for Its Eighth Annual Communications Grant Program Yahoo Finance

Cytokinetics Presents New Data Related to Aficamten at the European Society of Cardiology Congress 2025 - Cytokinetics

Cytokinetics Presents New Data Related to Aficamten at the European Society of Cardiology Congress 2025 Cytokinetics

Cytokinetics to Present Positive Aficamten Results at ESC Congress 2025 with Investor Webcast Scheduled for September 2, 2025 | CYTK Stock News - Quiver Quantitative

Cytokinetics to Present Positive Aficamten Results at ESC Congress 2025 with Investor Webcast Scheduled for September 2, 2025 | CYTK Stock News Quiver Quantitative

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - GlobeNewswire

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) GlobeNewswire

Cytokinetics Presents New Data Related to Aficamten at the HFSA Annual Scientific Meeting 2025 - GlobeNewswire

Cytokinetics Presents New Data Related to Aficamten at the HFSA Annual Scientific Meeting 2025 GlobeNewswire

Cytokinetics Names Jim Daly to Board of Directors - GlobeNewswire

Cytokinetics Names Jim Daly to Board of Directors GlobeNewswire

Cytokinetics Announces Three Upcoming Presentations at the HFSA Annual Scientific Meeting 2025 - GlobeNewswire

Cytokinetics Announces Three Upcoming Presentations at the HFSA Annual Scientific Meeting 2025 GlobeNewswire

Cytokinetics Appoints James M. Daly to Board of Directors - Quiver Quantitative

Cytokinetics Appoints James M. Daly to Board of Directors Quiver Quantitative

Cytokinetics to Present Corporate Update at Stifel 2025 Virtual Cardiometabolic Forum on September 30 - Quiver Quantitative

Cytokinetics to Present Corporate Update at Stifel 2025 Virtual Cardiometabolic Forum on September 30 Quiver Quantitative

Back-to-Back Healthcare Conferences: Cytokinetics Leadership to Present at Citi, Wells Fargo, Cantor, Morgan Stanley - Stock Titan

Back-to-Back Healthcare Conferences: Cytokinetics Leadership to Present at Citi, Wells Fargo, Cantor, Morgan Stanley Stock Titan

Major HCM Drug Trial Results: Cytokinetics' Aficamten vs Metoprolol Data Coming at ESC Congress 2025 - Stock Titan

Major HCM Drug Trial Results: Cytokinetics' Aficamten vs Metoprolol Data Coming at ESC Congress 2025 Stock Titan

Cytokinetics to Showcase Positive Aficamten Results for Obstructive Hypertrophic Cardiomyopathy at European Society of Cardiology Congress 2025 | CYTK Stock News - Quiver Quantitative

Cytokinetics to Showcase Positive Aficamten Results for Obstructive Hypertrophic Cardiomyopathy at European Society of Cardiology Congress 2025 | CYTK Stock News Quiver Quantitative

Superior Heart Function Improvement: Cytokinetics' Aficamten Beats Standard Care in Major HCM Clinical Trial - Stock Titan

Superior Heart Function Improvement: Cytokinetics' Aficamten Beats Standard Care in Major HCM Clinical Trial Stock Titan

Former Incyte & Amgen Commercial Leader Jim Daly Joins Cytokinetics Board as Company Preps Commercial Push - Stock Titan

Former Incyte & Amgen Commercial Leader Jim Daly Joins Cytokinetics Board as Company Preps Commercial Push Stock Titan

Cytokinetics Reports Fourth Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire

Cytokinetics Reports Fourth Quarter 2024 Financial Results and Provides Business Update GlobeNewswire

Cytokinetics Sets Key Q2 Earnings Date: What Investors Should Watch on August 7 - Stock Titan

Cytokinetics Sets Key Q2 Earnings Date: What Investors Should Watch on August 7 Stock Titan

Cytokinetics Announces New PDUFA Date for Aficamten in Obstructive Hypertrophic Cardiomyopathy - GlobeNewswire

Cytokinetics Announces New PDUFA Date for Aficamten in Obstructive Hypertrophic Cardiomyopathy GlobeNewswire

Cytokinetics Unveils $20,000 Grants for Healthcare Equity and Diversity: How Non-Profits Can Apply - Stock Titan

Cytokinetics Unveils $20,000 Grants for Healthcare Equity and Diversity: How Non-Profits Can Apply Stock Titan

Cytokinetics Announces 2025 Corporate Milestones and Vision 2030 - GlobeNewswire

Cytokinetics Announces 2025 Corporate Milestones and Vision 2030 GlobeNewswire

Cytokinetics Announces Start of AMBER-HFpEF, a Phase 2 - GlobeNewswire

Cytokinetics Announces Start of AMBER-HFpEF, a Phase 2 GlobeNewswire

Cytokinetics Announces Sanofi Acquired Rights to Develop and Commercialize Aficamten in Greater China - GlobeNewswire

Cytokinetics Announces Sanofi Acquired Rights to Develop and Commercialize Aficamten in Greater China GlobeNewswire

Cytokinetics Announces European Medicines Agency Validation - GlobeNewswire

Cytokinetics Announces European Medicines Agency Validation GlobeNewswire

Cytokinetics Names Robert E. Landry to Board of Directors - The Manila Times

Cytokinetics Names Robert E. Landry to Board of Directors The Manila Times

Cytokinetics and Bayer Announce Exclusive Licensing Collaboration for Aficamten in Japan - GlobeNewswire

Cytokinetics and Bayer Announce Exclusive Licensing Collaboration for Aficamten in Japan GlobeNewswire

Cytokinetics Announces Initiation of Phase 1 Clinical Study of CK-4015089 - GlobeNewswire

Cytokinetics Announces Initiation of Phase 1 Clinical Study of CK-4015089 GlobeNewswire

Cytokinetics Announces Call for Proposals for Its Seventh Annual Communications Grant Program - Yahoo Finance

Cytokinetics Announces Call for Proposals for Its Seventh Annual Communications Grant Program Yahoo Finance

Cytokinetics Announces Primary Results From SEQUOIA-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress and Published in the New England Journal of Medicine - Yahoo Finance

Cytokinetics Announces Primary Results From SEQUOIA-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress and Published in the New England Journal of Medicine Yahoo Finance

Cytokinetics Announces Licensing Collaboration and Royalty - GlobeNewswire

Cytokinetics Announces Licensing Collaboration and Royalty GlobeNewswire

Top Cytokinetics Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant